Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STAT1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Inhalation
01
Overview
STAT1 siRNA is a small interfering RNA designed to silence the expression of the Signal Transducer and Activator of Transcription 1 (STAT1) protein. In the context of sickle cell disease (SCD) research, STAT1 has been identified as a recruitment partner for 8-Oxoguanine DNA Glycosylase 1 (OGG1) in promoting inflammatory responses. By utilizing STAT1 siRNA to knock down STAT1 levels in macrophages, researchers have demonstrated a significant reduction in the expression of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. This suggests that targeting the STAT1 pathway may be a potential therapeutic strategy for managing inflammation in SCD.
- Other names
- STAT1-unique siRNAsSTAT-1-unique siRNAsSTAT 1-unique siRNAssiRNA targeting STAT1
02
Targets
Signal transducer and activator of transcription 1 (STAT1) mRNASTAT1 (Signal transducer and activator of transcription 1-alpha/beta)
Beyond the preview
Go deeper on STAT1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAT1 siRNA.